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On March 18, 2016, this report was posted as an MMWR 
Early Release on the MMWR website (http://www.cdc.gov/mmwr).
Zika virus is an emerging mosquito-borne flavivirus. Recent 
outbreaks of Zika virus disease in the Pacific Islands and 
the Region of the Americas have identified new modes of 
transmission and clinical manifestations, including adverse 
pregnancy outcomes. However, data on the epidemiology and 
clinical findings of laboratory-confirmed Zika virus disease 
remain limited. During January 1, 2015–February 26, 2016, 
a total of 116 residents of 33 U.S. states and the District 
of Columbia had laboratory evidence of recent Zika virus 
infection based on testing performed at CDC. Cases included 
one congenital infection and 115 persons who reported recent 
travel to areas with active Zika virus transmission (n = 110) or 
sexual contact with such a traveler (n = 5). All 115 patients had 
clinical illness, with the most common signs and symptoms 
being rash (98%; n = 113), fever (82%; 94), and arthralgia 
(66%; 76). Health care providers should educate patients, 
particularly pregnant women, about the risks for, and measures 
to prevent, infection with Zika virus and other mosquito-borne 
viruses. Zika virus disease should be considered in patients with 
acute onset of fever, rash, arthralgia, or conjunctivitis, who 
traveled to areas with ongoing Zika virus transmission (http://
www.cdc.gov/zika/geo/index.html) or who had unprotected sex 
with a person who traveled to one of those areas and developed 
compatible symptoms within 2 weeks of returning.
Zika virus is primarily transmitted to humans by Aedes aegypti 
mosquitoes (1). Most infections are asymptomatic (2). When 
occurring, clinical illness is generally mild and characterized 
by acute onset of fever, maculopapular rash, arthralgia, or 
nonpurulent conjunctivitis. Symptoms usually last from several 
days to a week. Severe disease requiring hospitalization is 
uncommon, and deaths are rare.
In addition to mosquito-borne transmission, Zika virus 
infections have been reported through intrauterine transmission 
resulting in congenital infection, intrapartum transmission 
from a viremic mother to her newborn, sexual transmission, 
and laboratory exposure (3,4). Increasing evidence suggests 
that Zika virus infection during pregnancy can result in 
microcephaly, other congenital anomalies, and fetal losses (5). 
Guillain-Barré syndrome also has been associated with recent 
Zika virus disease (6). However, the frequency of these outcomes 
is not known. To characterize Zika virus disease among U.S. 
residents, CDC reviewed demographics, exposures, and reported 
symptoms of patients with laboratory-evidence of recent Zika 
virus infection in the United States.
Zika virus disease cases among residents of U.S. states with 
specimens tested at CDC’s Arboviral Diseases Branch during 
January 1, 2015–February 26, 2016 were identified. The cases 
included in this report had laboratory evidence of Zika virus 
infection based on the following findings in serum: 1) Zika 
virus RNA detected by reverse transcription-polymerase chain 
reaction (RT-PCR); 2) anti-Zika virus immunoglobulin M 
(IgM) antibodies detected by enzyme-linked immunosorbent 
assay (ELISA) with ≥4-fold higher neutralizing antibody titers 
against Zika virus compared with neutralizing antibody titers 
against dengue virus; or 3) anti-Zika virus IgM antibodies 
with <4-fold difference in neutralizing antibody titers 
between Zika and dengue viruses and a direct epidemiologic 
link to a person with laboratory evidence of recent Zika virus 
infection (i.e., vertical transmission from mother to baby or 
sexual contact). State and local health departments collected 
information on patient demographics, dates of travel, and 
clinical signs and symptoms.
During January 1, 2015–February 26, 2016, a total of 
116 residents of 33 states and the District of Columbia 
with laboratory evidence of recent Zika virus infection were 
identified on the basis of testing at CDC. One case occurred 
in a full-term infant born with severe congenital microcephaly, 
whose mother had Zika virus disease in Brazil during the first 
trimester of pregnancy (5). Among the remaining 115 patients 
(including the infant’s mother), 24 (21%) had illness onset in 
2015 and 91 (79%) in 2016. Seventy-five (65%) cases occurred 
in females (Table 1). The median age of patients was 38 years 
(range = 3–81 years); 11 (10%) cases occurred in children and 
adolescents aged <18 years. Of the 115 patients, 110 (96%) 
reported recent travel to areas of active Zika virus transmission 
and five (4%) did not travel but reported sexual contact with 
a traveler who had symptomatic illness. The most frequently 
reported countries with active Zika virus transmission visited by 
patients were Haiti (n = 27), El Salvador (16), Colombia (11), 
Honduras (11), and Guatemala (10).
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All 115 patients reported a clinical illness with onset during 
March 2015–February 2016 (Figure). The most commonly 
reported signs and symptoms were rash (98%), fever (82%), 
arthralgia (66%), headache (57%), myalgia (55%), and 
conjunctivitis (37%) (Table 2). Among all 115 patients, 110 
(96%) reported two or more of the following symptoms: rash, 
fever, arthralgia, and conjunctivitis; 75 (65%) reported three 
or more of these signs or symptoms. Four (3%) patients were 
hospitalized; no deaths occurred. Among the 109 travelers 
who had known travel dates, patients reported becoming ill a 
median of 1 day after returning home (range = 37 days before 
return to 11 days after return).
Laboratory evidence of Zika virus infection included 
positive RT-PCR test results in 28 (24%) cases and positive 
serologic test results in 87 (76%) cases; two (2%) cases had 
serologic evidence of a recent unspecified flavivirus infection 
and were classified as Zika virus disease cases based on 
their epidemiologic link to a confirmed case (one vertical 
transmission and one sexual contact).
Discussion
Before 2015, Zika virus disease among U.S. travelers was 
uncommon. This likely was because of low levels of Zika 
virus transmission in travel destinations and limited disease 
recognition in the United States. Local mosquito-borne 
transmission of Zika virus has not been documented in U.S. 
states. With the recent outbreaks in the Americas, the number 
of Zika virus disease cases among travelers visiting or returning 
to the United States has increased and will likely continue to 
increase. These imported cases might result in local human-
to-mosquito-to-human transmission of the virus in U.S. states 
that have the appropriate mosquito vectors.
This report increases the number of laboratory-confirmed 
sexually transmitted Zika virus disease cases reported in the 
United States; two cases included here were previously reported as 
probable cases and were confirmed through additional testing (4). 
Sexually transmitted cases will be increasingly recognized among 
contacts of returning travelers and there is risk for congenital, 
perinatal, or transfusion-associated transmission. CDC has issued 
guidelines to reduce the risk for travel-associated infections, 
especially among pregnant women and sexual contacts of travelers 
(4,7). Temporary deferral of blood donors with recent travel to 
Zika-affected areas also has been recommended to reduce the risk 
for transfusion-associated transmission (8).
The cases presented in this report have clinical findings 
similar to those of Zika virus disease cases previously reported 
from other countries. Most had fever and rash; however, rates 
of conjunctivitis are lower than those seen in previous outbreaks 
(2). The majority (95%) of cases occurred in travelers to areas 
with ongoing mosquito-borne Zika virus transmission.
This evaluation was limited to cases with testing performed 
at CDC through February 26, 2016. Zika virus RT-PCR and 
anti-Zika IgM antibody testing is now available at an increasing 
number of state, territorial, and local health departments, and 
additional cases have been diagnosed and reported from state 
and territorial health departments beyond those included in 
this report (http://www.cdc.gov/zika/geo/united-states.html). 
On February 26, 2016, the Council of State and Territorial 
Epidemiologists (CSTE) approved interim case definitions 
for Zika virus disease and Zika virus congenital infection and 
added them to the list of nationally notifiable conditions (9). 
Subsequent reports of Zika virus disease cases will include 
cases reported to ArboNET, the national arboviral surveillance 
system, using the interim CSTE case definitions.
Health care providers should educate patients about the 
risks for Zika virus disease and measures to prevent Zika virus 
infection and other mosquito-borne infections. Zika virus 
disease should be considered in patients with acute onset 
of fever, rash, arthralgia, or conjunctivitis who traveled to 
areas with ongoing transmission or had unprotected sex with 
someone who traveled to those areas and developed compatible 
symptoms within 2 weeks of returning. Until more is known 
about the effects of Zika virus infection on the developing fetus, 
pregnant women should postpone travel to areas where Zika 
virus transmission is ongoing. Pregnant women who do travel 
to one of these areas should talk to their health care provider 
before traveling and strictly follow steps to avoid mosquito 
TABLE 1. Characteristics of 115 residents of U.S. states and the District 
of Columbia with laboratory evidence of Zika virus disease — 
January 1, 2015–February 26, 2016*,†
Characteristic No. (%)
Female 75 (65)
Age group (yrs)
<10 4 (3)
10–19 10 (9)
20–29 23 (20)
30–39 22 (19)
40–49 19 (17)
50–59 23 (20)
60–69 13 (11)
≥70 1 (1)
Region visited
Central America 42 (37)
Caribbean 38 (33)
South America 21 (18)
Southeast Asia and Pacific Islands 7 (6)
North America (Mexico) 2 (2)
No travel§ 5 (4)
Hospitalized 4 (3)
Died 0 (0)
* Testing performed at CDC’s Arboviral Diseases Branch laboratory.
† Excludes one infant born with severe congenital microcephaly after maternal 
infection in Brazil during the first trimester of pregnancy.
§ Sexual contacts of travelers.
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with Zika virus transmission should be tested for Zika virus 
infection; testing may also be offered to asymptomatic pregnant 
women 2–12 weeks after travel to an area with active Zika 
transmission (7). Fetuses and infants of women infected with 
Zika virus during pregnancy should be evaluated for possible 
congenital infection (10). CDC has established a registry to 
collect information on Zika virus infection during pregnancy 
and congenital infection.*
Health care providers are encouraged to report suspected Zika 
virus disease cases to their state or local health departments to 
facilitate diagnosis and mitigate the risk for local transmission 
in areas where Aedes aegypti or Aedes albopictus mosquitoes 
are currently active. State health departments should report 
laboratory-confirmed cases of Zika virus disease to CDC (8).
TABLE 2. Clinical signs and symptoms reported by 115 residents of 
U.S. states and the District of Columbia with laboratory evidence of 
Zika virus disease — January 1, 2015–February 26, 2016*
Sign/symptom
Yes† No Unknown
No. (%) No. (%) No. (%)
Rash 113 (98) 1 (1) 1 (1)
Fever 94 (82) 20 (17) 1 (1)
Arthralgia 76 (66) 33 (29) 6 (5)
Headache 65 (57) 37 (32) 13 (11)
Myalgia 63 (55) 38 (33) 14 (12)
Conjunctivitis 43 (37) 53 (46) 19 (17)
Diarrhea 22 (19) 63 (55) 30 (26)
Vomiting 6 (5) 79 (69) 30 (26)
* Testing performed at CDC’s Arboviral Diseases Branch laboratory.
† Some patients had more than one sign and/or symptom.
* Please send inquiries about the pregnancy registry to ZikaPregnancy@cdc.gov.
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FIGURE. Month of illness onset for 115 patients with laboratory evidence of Zika virus infection among residents of U.S. states and the District 
of Columbia — January 1, 2015–February 26, 2016*
* Testing performed at CDC’s Arboviral Diseases Branch laboratory.
bites (http://www.cdc.gov/features/stopmosquitoes/) during 
travel. Pregnant women who develop a clinically compatible 
illness during or within 2 weeks of returning from an area 
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Summary
What is already known about this topic?
Zika virus is an emerging mosquito-borne flavivirus. Recent 
outbreaks of Zika virus disease in the Pacific Islands and the Region 
of the Americas have identified new modes of transmission and 
clinical manifestations, including adverse pregnancy outcomes.
What is added by this report?
During January 1, 2015–February 26, 2016, a total of 
116 residents of U.S. states and the District of Columbia had 
laboratory evidence of recent Zika virus infection based on 
testing performed at CDC, including one congenital infection 
and 115 persons who reported recent travel to areas with active 
Zika virus transmission (n = 110) or sexual contact with such a 
traveler (n = 5).
What are the implications for public health practice?
Health care providers should educate patients about the risks for 
Zika virus disease and measures to prevent Zika virus infection 
and other mosquito-borne infections. Zika virus disease should 
be considered in patients with acute onset of fever, rash, 
arthralgia, or conjunctivitis who traveled to areas with ongoing 
transmission or had unprotected sex with someone who traveled 
to those areas and developed compatible symptoms within 2 
weeks of returning.
